FDA warned Integra LifeSciences over collagen-based medical devices made in Boston after an inspection found quality-system failures and endotoxin testing problems.
What happened
FDA inspected TEI Biosciences, an Integra LifeSciences company, in Boston, MA, from March 1 through May 17, 2023. FDA found the collagen-based devices were adulterated (not meeting legal manufacturing requirements) because manufacturing and quality controls did not meet the Quality System regulation. The company recalled all finished goods within expiry manufactured from March 1, 2018 through May 22, 2023, and committed not to distribute until the site was in substantial conformity.
What FDA found
Failed to have procedures to control product that did not meet specifications; a Durepair lot was released despite a bacterial endotoxin result above the limit.
21 CFR 820.90(a)Failed to have effective corrective and preventive action procedures; a complaint led to a hold, but actions were not opened for all issues, including endotoxin.
21 CFR 820.100(a)(1)Failed to adequately validate test methods for bacterial endotoxin and bioburden testing.
21 CFR 820.75(a)Failed to store devices to allow proper stock rotation and assess condition; sterile implantable lots labeled non-sterile were on an unsecure open shelf in quarantine.
21 CFR 820.150(a)
What FDA wants
FDA asks the company to respond in writing within 15 business days with the specific steps and corrective actions it has taken or plans to take to prevent recurrence. It also requests certification by an outside expert consultant that an audit of manufacturing and quality assurance systems was conducted, with initial certifications due March 31, 2024.
Who should pay attention
- hospitals and surgeons implanting collagen-based devices
- distributors and buyers of recalled Integra/TEI products
- other medical device manufacturers with collagen or implantable products
This is a summary. Read the original letter on fda.gov.